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ABSTRACT HIV-1 reverse transcriptase (RT) is the primary target for anti-AIDS chemotherapy. Nonnucleoside RT inhibitors
(NNRTIs) are very potent and most promising anti-AIDS drugs that speciﬁcally inhibit HIV-1 RT. The binding and unbinding
processes of a-APA, an NNRTI, have been studied using nanosecond conventional molecular dynamics and steered molecular
dynamics simulations. The simulation results show that the unbinding process of a-APA consists of three phases based on the
position of a-APA in relation to the entrance of the binding pocket. When a-APA is bound in the binding pocket, the hydrophobic
interactions between HIV-1 RT and a-APA dominate the binding; however, the hydrophilic interactions (both direct and water-
bridged hydrogen bonds) also contribute to the stabilizing forces. Whereas Tyr-181 makes signiﬁcant hydrophobic interactions
with a-APA, Tyr-188 forms a strong hydrogen bond with the acylamino group (N14) of a-APA. These two residues have very
ﬂexible side chains and appear to act as two ‘‘ﬂexible clamps’’ discouraging a-APA to dissociate from the binding pocket. At the
pocket entrance, two relatively inﬂexible residues, Val-179 and Leu-100, gauge the openness of the entrance and form the
bottleneck of the inhibitor-unbinding pathway. Two special water molecules at the pocket entrance appear to play important
roles in inhibitor recognition of binding and unbinding. These water molecules form water bridges between the polar groups of
the inhibitor and the residues around the entrance, and between the polar groups of the inhibitor themselves. The water-bridged
interactions not only induce the inhibitor to adopt an energetically favorable conformation so the inhibitor can pass through
the pocket entrance, but also stabilize the binding of the inhibitor in the pocket to prevent the inhibitor’s dissociation. The
complementary steered molecular dynamics and conventional molecular dynamics simulation results strongly support the
hypothesis that NNRTIs inhibit HIV-1 RT polymerization activity by enlarging the DNA-binding cleft and restricting the ﬂexibility
and mobility of the p66 thumb subdomain that are believed to be essential during DNA translocation and polymerization.
INTRODUCTION
Human immunodeﬁciency virus type 1 reverse transcriptase
(HIV-1 RT) is one of the most important antiretroviral tar-
gets in the chemotherapy of acquired immune deﬁciency
syndrome (AIDS) patients. The drug discovery researches
targeting on HIV-1 RT have been extensively enhanced in
the past two decades (De Clercq, 1996, 1998, 1999, 2001,
2002; Sala and Vartanian, 1998; Turner and Summers, 1999;
Chen et al., 2000; Buckheit, 2001; Gupta, 2002; Campiani
et al., 2002). Currently approved drugs targeting on HIV-1
RT to treat HIV infection fall mainly into two classes:
nucleoside-analogous RT inhibitors (NRTIs) and nonnucleo-
side RT inhibitors (NNRTIs). NRTIs, such as 39-azido-39-
deoxythymidine (AZT), 29,39-dideoxyinosine (ddI) and
29,39-dideoxycytidine (ddC), are competitive inhibitors that
bind at the deoxynucleoside triphosphate (dNTP) binding
pocket and function as chain terminator in DNA elongation.
These inhibitors are effective in inhibiting HIV-1 RT;
however, their application is limited due to the high
cytotoxicity (inhibition to other normal polymerization
process in vivo) and the emergence of drug-resistant mutants
(reviewed in Larder, 1993; Tantillo et al., 1994; De Clercq,
1994, 2001; Ding et al., 1997). NNRTIs are a chemically
diverse set of compounds with high speciﬁcity to HIV-1 RT
and, therefore, have the potential to become the most
promising anti-AIDS drugs. Three NNRTIs, Nevirapine (a
dipyridodiazepinone derivative), Delavirdine (BHAP U-
90152), and Efavirenz, have been approved by the U.S.
Food and Drug Administration (FDA) and are used in
combination with NRTIs and PIs (protease inhibitors) to treat
AIDS patients (De Clercq, 1998, 1999, 2001, 2002;
Buckheit, 2001; Gupta, 2002). However, similar to NRTIs,
NNRTIs’ Achilles heel is the emergence of drug resistant
mutations in the enzyme, and there is no ﬁnal treatment
solution to AIDS yet (Larder, 1993; Richman, 1993;
Campiani et al., 2002; De Clercq, 2002).
A number of high-resolution crystal structures of HIV-1
RT in complexing with NNRTIs in both wild-type and
mutant-type have been reported in the past decade (Kohl-
staedt et al., 1992; Ding et al., 1995a,b; Ren et al., 1995a,b,
2001; Das et al., 1996; Hsiou et al., 1998, 2001; Lindberg
et al., 2002). Crystal structures demonstrate that HIV-1 RT is
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composed by two subunits, p66 and p51, and that NNRTIs
bind to the p66 subunit. The three-dimensional (3D) model of
the p66 subunit is schematically represented in Fig. 1. In
general, the structure of p66 looks like a human hand,
comprising ﬁngers subdomain, thumb subdomain, palm
subdomain, and connection subdomain linking with Rnase
H subdomain (not shown in Fig. 1). The apoenzyme adopts
a ‘‘close’’ conformation in which the p66 thumb subdomain
folds down into the DNA binding cleft and makes contacts
with the tip of ﬁngers (Jager et al., 1994; Esnouf et al., 1997;
Rodgers et al., 1995; Hsiou et al., 1996). Binding with
template-primer of DNA or inhibitors, the p66 thumb
subdomain takes an upright or ‘‘open’’ conformation and,
together with the p66 ﬁngers and palm subdomains, forms
a large cleft to accommodate the template-primer substrate
(Jacobo-Molina et al., 1993; Ding et al., 1998). Interestingly,
NNRTIs can burrow a naturally inexistent hydrophobic
pocket to accommodate themselves. The NNRTI binding
pocket (NNIBP) is located;10 A˚ away from the polymerase
active site and is primarily consisted of Leu-100, Lys-101,
Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-
188, Val-189, Gly-190, Phe-227, Trp-229, Leu-234, and Tyr-
318 in p66 (Kohlstaedt et al., 1992; Ding et al., 1995a). The
putative entrance of the pocket is proposed to be located at the
interface of the p66/p51 heterodimer and is primarily formed
by Pro-95, Leu-100, Lys-101, Lys-103, Val-179, and Tyr-
181 of p66 (Ding et al., 1995a; Ren et al., 1995a; Esnouf,
et al., 1997). The side chains of several residues, especially
those of Tyr-181 and Tyr-188, assume signiﬁcant conforma-
tional changes on the binding of NNRTIs. The secondary
structural elements around the NNIBP rearrange as well in
comparison with the structure of the apoenzyme (Ding et al.,
1995a).
This unique ligand-enzyme interaction phenomenon raises
interesting questions: how do NNRTIs induce the formation
of the NNIBP? How do NNRTIs inhibit the polymerization
activity of HIV-1 RT? So far, no convincing data have been
reported concerning these two questions. To investigate the
microscopic dynamic processes of NNRTIs binding and the
formation of NNIBP, large scale conventional molecular
dynamics (CMD) and steered molecular dynamics (SMD)
simulations were performed. For the CMD simulation, the
inhibitor was harmonically constrained in the NNIBP; and
for the SMD simulation, a harmonic potential was applied to
the inhibitor to pull the inhibitor out from the binding pocket
artiﬁcially. Through simulations and comparisons with
various crystal structures of HIV-1 RT bound with and
without NNRTIs, we intend to explore the detailed protein-
inhibitor interactions related to inhibitor binding and
unbinding and gain insights into the inhibition mechanism
of NNRTIs to HIV-1 RT.
SMD is an extendedMD simulationmethodmimicking the
principle of the atomic force microscopy (AFM) (Binning
et al., 1986; Block and Svoboda, 1994; Evans et al., 1995).
SMD has been widely used to explore the binding and
unbinding properties of biomolecules and their responses to
external mechanical manipulations at the atomic level
(Izrailev et al., 1998). SMD has been successfully applied
to identify several ligand binding pathways (Grubmu¨ller et al.,
1996; Isralewitz et al., 1997; Stepaniants et al., 1997;Marrink
FIGURE 1 A schematic representa-
tion of the 3D structure feature of p66
subunit of HIV-1 RT and the diagram of
the SMD simulation system. The p66
subunit is shown in solid ribbon and
a-APA in ball-and-stick model. The
NNRTI binding pocket is represented
with the VDW surface. During the SMD
simulation, the bound a-APA is pulled
away from the binding pocket using a
harmonic potential symbolized by an
artiﬁcial spring that is connected to the
C12 atom of a-APA (labeled in green
color). This pulling potentialmoveswith
a constant velocity of 0.02 A˚/ps in the
direction indicated by the arrow. Three
snapshots of a-APA in the unbinding
pathway are shown, representing the ini-
tial state, the state passing through the
entrance of the binding pocket, and the
ﬁnal state in the SMD trajectory, respec-
tively. This picture was generated using
WebLab ViewerPro program (MSI,
1998) and rendered using the POV-Ray
program (Pov-Ray-Team, 1999). The
numbering of a-APA is shown in the
schematic diagram of a-APA.
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et al., 1998; Wriggers and Schulten, 1997) and to explain the
elastic properties of some proteins (Lu et al., 1998; Lu and
Schulten, 1999; Heymann and Grubmu¨ller, 1999a; Krammer
et al., 1999; Heymann and Grubmu¨ller, 2001). In SMD
simulations, time-dependent external forces are applied to
ligand to facilitate its unbinding with a protein as shown in
Fig. 1. From the accelerated dissociation process of the
ligand, SMD simulation can reveal information about the
enzyme’s ﬂexibility and its response to the dissociation of
ligand. Analyses of interactions between the dissociating
ligand and the protein (especially residues forming the
binding pocket) and the relationship between the applied
forces and the ligand position could yield important in-
formation about the structure-function relationships of the
protein-ligand complex, the binding and unbinding path-
way(s), and possible mechanisms of ligand recognition and
inhibition.
In this work, we present the molecular dynamics studies of
the unbinding process of a-APA, an NNRTI, to HIV-1 RT.
The simulation results show that the polar groups of a-APA
play important roles in inhibitor recognition and binding.
Water-bridged hydrogen bonds appear to not only mediate
the protein-inhibitor interactions but also induce conforma-
tional change of the inhibitor and, thus, facilitate the inhibitor
binding and unbinding. Comparison of the complementary
SMD and CMD simulation results strongly supports the
hypothesis that NNRTIs inhibit HIV-1 RT polymerization
activity by enlarging the DNA-binding cleft and restricting
the mobility of the p66 thumb subdomain.
MATERIAL AND METHODS
Molecular model
As a pregeneration of Loviride, a-APA is a typical NNRTI with high
activity (IC50 of 5 nM) and high selectivity (selectivity index of 84,000)
(Pauwels and Janssen, 1993). It is selected to explore the binding and
unbinding properties of NNRTIs in the present molecular dynamics
simulations. The simulation model was constructed based on the x-ray
crystal structure of HIV-1 RT/a-APA complex (PDB entry 1HNI) (Ding
et al., 1995a). The side chains with missing coordinates in the crystal
structure were reconstructed using the fragment library of the Biopolymer
module in Sybyl version 6.7 (Tripos Inc., 1999). The modiﬁed structure was
subjected to energy minimization using steepest descent method up to the
gradient tolerance of 0.05 kcal/(molA˚) to relieve possible steric clashes and
overlaps of side chains.
The entire structure of the HIV-1 RT/a-APA complex is too large to be
simulated by our current computational facilities. Structural and bio-
chemical data indicate that the NNIBP is mainly composed of structural
elements of the p66 subunit (Kohlstaedt et al., 1992; Ding et al., 1995a; Ren
et al., 1995a) and that the RNase H subdomain and the p51 subunit are not
directly involved in NNRTI binding and play a minor role in the sensitivity
to NNRTIs (Boyer et al., 1992; Auwerx et al., 2002). Therefore, in the
current simulation studies, both the RNase H subdomain and the p51 subunit
were omitted to facilitate the simulation and save the computation time.
The simulation model was solvated into a TIP3P (Jorgensen et al., 1983;
Neria et al., 1996) water sphere droplet with a radius of 52 A˚ using the
program SOLVATE (Grubmu¨ller, 1996). The large solvent radius ensures
the whole protein surface to be covered by water molecules at least 12 A˚
thick, which is large enough for the conformational change of HIV-1 RT
model within the water sphere. Moreover, a layer of 4 A˚ thick in the brim of
the droplet was subjected to SBOUND forces (Brooks and Karplus, 1983) to
ensure that the water molecules at the edge are restrained in a given volume.
In total, the simulation system contains 3927 protein atoms, 26 inhibitor
atoms, and 52,000 water molecule atoms.
MD simulations
The MD simulations were performed with the parallelized MD program
EGO (Eichinger and Grubmu¨ller, 1996) running on an SW-I supercomputer
at the Shanghai Supercomputer Center. CHARMM19 force ﬁeld (Brooks
et al., 1983) was adopted in the program. The force ﬁeld of a-APA was
generated using program XPLO2D (Kleywegt and Jones, 1997) and the
partial atomic charges of a-APA were determined using the RESP ﬁtting
method (Bayly et al., 1993) implemented in the NWChem software package
version 3.3.1 (Anchell et al., 1998). All simulations were carried out with an
integration step of 1 fs and coordinates of the simulation model were
recorded per 1 ps. Translation and rotation corrections were enabled during
MD simulations to ensure that structures in trajectory were well super-
imposed, which is convenient for the structure analysis. The chemical bond
lengths involving hydrogen atoms were ﬁxed with SHAKE algorithm
(Brooks and Karplus, 1983). The application of EGO program in large-scale
molecular dynamics simulations has been reviewed by Eichinger et al.
(2000).
The solvated model was ﬁrst minimized using the minimization routine
of EGO to reduce steric conﬂicts between water molecules and the protein.
During minimization, the velocities of atoms were rescaled by a friction
factor t of 0.1 at the end of each integration step, and the maximal positional
movement of atoms per integration step was set to be no more than 0.08 A˚.
The solvent molecules in the minimized model were then heated up to 300 K
and equilibrated with the protein coordinates being constrained until the total
energy of the system reaches a stable state. Finally, the whole solvated
model was heated up to 300 K by a coupling constant of 0.1 ps and then
subjected to a free equilibrium simulation for 900 ps with a-APA being
harmonically constrained in the binding pocket. By the time of 900 ps, the
simulation system reached an equilibrium state (see Results and Discussion);
thus, the system was subjected to two MD simulations simultaneously: one
is an SMD simulation and the other is a conventional MD (CMD) simulation
for comparison.
In the SMD simulation, the bound a-APA was pulled out from the
binding pocket of HIV-1 RT by employing an artiﬁcial harmonic potential
on a-APA as shown by the symbolic ‘‘spring’’ in Fig. 1. Based on the
averaged conformation between 800–900 ps, the moving direction of a-
APA was determined using the criterion that the inhibitor can pass through
the putative entrance with the smallest collision with the protein residues
(mainly considering the collisions with Lys-101, Lys-103, and Val-179;
see Results and Discussion). Translation and rotation corrections of the
protein were switched on for the convenience of the structure analysis; the
translation and rotation corrections of a-APA were switched off, and thus
it can adjust its orientation during moving. Because of switching on the
rotation correction for the protein, if the potential is applied to the end
atom of the ligand as previous SMD did, it is possible that the ligand may
not adjust its orientation once the moiety around the potential assigned
atom rams the protein. However, assigning the pulling potential to an atom
close to the center of mass (CM) of the ligand may overcome this problem
because CM has low possibility to clash the pocket wall of the protein
and, moreover, the two ends of the ligand divided by the CM have
ﬂexibility to avoid the clash with the protein. Therefore, the pulling
potential was assigned to atom C12 of a-APA that is close to the center of
mass of the inhibitor molecule. To mimic the unbinding process of
NNRTIs in the real biological system, the pulling speed of the spring
potential was ﬁxed at 0.02 A˚/ps and the spring constant was set to be 4
kcal/(molA˚2). The SMD simulation ran for 2 ns. After the inhibitor was
completely pulled out of the binding pocket and entered the solvent
region, the SMD simulation system was continued with a CMD simulation
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for additional 1 ns. For comparison, the parallel CMD simulation was
performed for a similar time period in which a-APA was harmonically
constrained in the binding pocket.
Quantum mechanics calculation
Substantial conformational changes of a-APA have been observed to occur
during the SMD simulation, and water-bridged interactions appear to play
important role(s) in inhibitor binding and unbinding (see Results and Dis-
cussion). To examine the energetic properties of different a-APA conforma-
tions and the effects of water-bridged interactions in the inhibitor unbinding
process, models of typical a-APA conformations with and without water
molecules bound at different time of the SMD trajectory were recorded, and
their relative energies were computed using the electronic correlation quan-
tum mechanics method Mo¨ller-Plesset second order perturbation (MP2)
(Pople andHead-Gordon, 1988; Saebo andAlmlof, 1989; Perdew andWang,
1992) at the 6-31G** basis set level. All quantum mechanics calculations




The testing CMD simulations indicated that a-APA might
depart from the equilibrious position in the binding pocket
during the MD simulation. To keep a-APA moving only
around its equilibrious position derived from the x-ray
structure, harmonic constraint was assigned to the heavy
atoms of a-APA with a coefﬁcient of 0.1 kcal/(molA˚2) in
the CMD simulations, including the MD simulation for
system equilibration.
System temperature and total energy of the simulation
model versus simulation time are shown in Fig. 2, A and B,
which indicates that the system temperature is coupled at 300
K and the total energy ﬂuctuates within less than 0.7% after
short time equilibration. The main chain root mean square
deviation (RMSD) from the starting structure is an important
criterion for the convergence of the protein system. The
RMSDs of the main chains of the whole model and residues
composing the binding pocket are also shown in Fig. 2, C
and D, which indicate that both the whole simulation system
and the binding pocket appear to have been stabilized after
750 ps equilibration. Hence, at the time of 900 ps, the system
was subjected to two different MD simulations: a CMD
simulation in which a-APA was harmonically constrained in
the binding pocket, and an SMD simulation in which a-APA
was pulled out from the binding pocket by an artiﬁcial
external potential. The SMD simulation started from 900 ps
and ended at 1873 ps. At this time, a-APA had been
completely pulled out of the binding pocket and entered into
the solvent region. Therefore, the SMD simulation was
terminated and the simulation system was continued with an
additional 1 ns CMD simulation (from 1873 to 3000 ns). The
parallel CMD simulation started from 900 ps and ended at
2500 ps.
Three phases of the inhibitor unbinding process
Before the SMD simulation, a-APA is tightly bound in
the NNIBP and the pocket entrance is narrowly open. In the
SMD simulation, the bound a-APA dissociates from the
binding pocket, passes through the pocket entrance, and
ﬁnally enters the solvent region. Analyses of the SMD
simulation trajectory and the protein-inhibitor interactions
suggest that the unbinding process of a-APA can be divided
FIGURE 2 The temperature (A) and
total energy (B) ﬂuctuations and the
RMSDs of the main chain of the whole
model (C) and the residues composing
the binding pocket (Pro-95–Thr-108,
Val-179–Tyr-181, Tyr-188–Gly-191,
Phe-227–Trp-229, Val-234–Pro-236,
and Tyr-318) (D) of the simulation
system in the free equilibrium period.
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into three phases based on the position of a-APA in relation
to the inhibitor-binding pocket (Figs. 3–5, see discussions
later). In phase I (from 900 to 1150 ps), a-APA dissociates
from the binding pocket and moves toward the pocket
entrance. In phase II (from 1150 to 1300 ps), a-APA
overcomes the steric conﬂicts with the residues at the
entrance and passes through the entrance of the pocket. After
crossing over the entrance and exiting the binding pocket, the
unbinding process enters phase III. During this phase (from
1300 to 1600 ps), a-APA moves further away from the
binding pocket and enters the solvent region.
Correlation of the rupture force with
the protein-inhibitor interactions
The rupture force proﬁle derived from the SMD simulation
shows multiple force peaks and troughs, implying that the
unbinding process of the inhibitor might be complicated
(Fig. 3). To probe the relationship between the calculated
pulling forces and the protein-inhibitor interactions, 12
speciﬁc snapshots of the simulation model along the
unbinding pathway were taken, corresponding to ﬁve force
peaks (925, 997, 1095, 1205, and 1250 ps) and seven force
troughs (935, 1010, 1150, 1240, 1280, 1345, and 1460 ps)
in Fig. 4. For each snapshot, three types of interactions be-
tween HIV-1 RT and a-APA, the direct hydrogen-bonding
interaction (DHBI), water-bridged interaction (inhibitor-
protein interaction via water molecule, WBI), and hydro-
phobic interaction (HI), were analyzed using LIGPLOT
program (Wallace et al., 1995) (Fig. 5). LIGPOT expresses
the hydrophobic interaction as van der Waals contacts
involving nonpolar atoms between a ligand and a protein.
We use the number of van der Waals contacts of nonpolar
atoms (NPAVDWs) to represent the hydrophobic interaction
strength throughout this paper.
Along the inhibitor-unbinding pathway, the interactions
between a-APA and HIV-1 RT change from time to time
(Figs. 4 and 5). Overall, the hydrophobic interactions dec-
rease gradually from phases I to III; the hydrogen-bonding
interactions increase from phases I to II and decrease from
phases II to III; and the water-bridged interactions decrease
slightly from phases I to II and increase moderately from
phases II to III (Figs. 4 and 5). The DHBIs andWBIs in phase
II are particularly different from the other two phases, which
is apparently related to the passage of a-APA through the
entrance of the pocket (see discussions later).
In phase I, owing to the hydrophobic nature of both the
NNIBP and the inhibitor, the interactions between a-APA
and HIV-1 RT are dominated by the hydrophobic inter-
actions. The number of the van der Waals contacts involving
nonpolar atoms (NPAVDWs) reaches as high as 25 (Fig. 5
C). The hydrophilic interactions (including both DHBIs and
WBIs) are less signiﬁcant (always less than 3 each), but
appear to play important roles in stabilizing the inhibitor
binding (Fig. 5, A and B). The acylamino group (N14) of
a-APA forms two direct hydrogen bonds with the carbonyl O
atoms of Tyr-188 and Val-179, respectively, and two water-
bridged interactions with Thr-107 and Val-189 (Fig. 4, A–E).
Similar hydrogen-bonding interactions have also been
observed in the crystal structure of HIV-1 RT/a-APA
complex (Ding et al., 1995a). The carbonyl group (O4) of
a-APA can also form one WBI with Lys-101 at the
beginning of the SMD simulation (Fig. 4 A).
In phase II, a-APA penetrates through the entrance of the
pocket. The hydrophobic interactions between a-APA and
HIV-1 RT become weak, but NPAVDWs are still more than
10 (Fig. 5 C). The DHBIs between the acylamino group
(N14) of a-APA and Tyr-188 and Val-179 still exist (Fig. 4,
F–J). In addition, a-APA forms a DHBI via its carbonyl O15
atom with the amide N atom of Gly-190. In this region, the
WBIs between a-APA and HIV-1 RT almost disappear.
Instead, a-APA forms several intramolecular interactions via
two special water molecules (Fig. 4, I and J). These water-
bridged intramolecular interactions assist a-APA to adopt
a proper conformation in a way that it can pass through the
entrance of the pocket (see discussion later).
After a-APA exited the binding pocket (phase III), the
hydrophobic interactions between a-APA and HIV-1 RT
become very weak (Fig. 5 C), and a-APA forms one DHBI
with the side chain Nz atom of Lys-103 and a few WBIs with
the residues at the outer rim of the entrance (Fig. 4, K and L).
As a-APA moves further away from the binding pocket
(after 1600 ps), it enters into the water solvent region and all
of its interactions with HIV-1 RT diminish gradually (Fig. 5).
During this period of time, a-APA forms hydrogen bonds
with the surrounding water molecules and the rupture force
comes primarily from the frictional force of water.
Comparison of Figs. 3 and 5 indicates that the rupture
force proﬁle correlates well with the interactions between
a-APA and HIV-1 RT. The stronger rupture force appears
to correspond to stronger interactions between a-APA and
HIV-1 RT. At the ﬁrst major force peak (at 997 ps), a-APA
FIGURE 3 Rupture force exerted on a-APA during inhibitor unbinding
versus simulation time at a pulling velocity of 0.02 A˚/ps. The pulling force
was smoothened with a Gaussian ﬁlter kernel of 10 ps width.
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FIGURE 4 Schematic diagrams
showing hydrogen-bonding, wa-
ter-bridged, and hydrophobic in-
teractions between a-APA and
HIV-1 RT at different stages of
the unbinding process. Amino
acid residues of HIV-1 RT that
havehydrophobic interactionswith
a-APA are shown as spiked
spheres (hydrophobic interactions
with distances of less than 3.5 A˚).
Direct and water-bridged hydro-
gen-bonding interactions are in-
dicated by dashed lines.
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FIGURE 4 Continued.
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forms ;20 pairs of NPAVDWs, 1 DHBI, and 2 WBIs with
HIV-1 RT. The largest force peak occurs at around 1095 ps,
where a-APA forms more than 20 pairs of NPAVDWs, 2
DHBI, and 2 WBIs with HIV-1 RT. At the third force peak
(at 1205 ps), a-APA may form 10 pairs of NPAVDWs, 1
DHBI, and 1 WBI with HIV-1 RT (Figs. 4 and 5).
A bottleneck of the inhibitor unbinding pathway
The putative entrance of NNIBP is proposed to be formed by
Pro-95, Leu-100, Lys-101, Lys-103, Val-179, and Tyr-181
of the p66 subdomain (Ding et al., 1995a; Ren et al., 1995a;
Esnouf, et al., 1997). Several important distances between
these residues were monitored during the SMD simulation.
Two of them that are of particular interest are the distance
between Nz atoms of Lys-101 and Lys-103 and the distance
betweenCa atom of Leu-100 andCg atom ofVal-179 (Fig. 6).
Lys-101 and Lys-103 are located at the rim of the entrance
(Figs. 1 and 7). Structural data show that these residues are
involved in the formation of a network of hydrogen bonds
at the entrance and might act as gatekeeper to discriminate
whether an NNRTI can enter into the binding pocket (Hsiou
et al., 2001). Biochemical data indicate that HIV-1 RT con-
taining mutations at residues 101 and 103 (especially Lys-
103-Asnmutation) confers signiﬁcant drug resistance to most
NNRTIs (Byrnes et al., 1993; Richman, 1993; De Clercq,
1998; Rubsamen-Waigmann et al., 1999; Kleim et al., 1999).
The SMD simulation results show that the side chains of Lys-
101 and Lys-103 are very ﬂexible. In phase I, the distance
between these two residues varies signiﬁcantly between 6 and
10 A˚ (Fig. 6 A). In phase II, this distance increases gradually
to ;9 A˚. In phase III, this distance ﬂuctuates between 8 and
10 A˚. After that, it drops to 5 A˚ and vibrates around 6 A˚. The
high ﬂexibility of these residues might play some roles in
inhibitors binding and/or unbinding processes.
Residues Val-179 and Leu-100 are located at the opposite
edges of the entrance. The simulation results show that the
side chains of Leu-100 and Val-179 are more rigid (Fig. 6 B).
The distance between Leu-100 and Val-179 ﬂuctuates only
slightly around 9 A˚ in phase I. As a-APA passes through the
entrance from inside of the pocket to the outside (phase II),
the distance between them increases gradually from 9 to 12
A˚. In phase III, as a-APA leaves further away from the
pocket the distance between Leu-100 and Val-179 decreases
a little bit to ;11 A˚ and keeps relatively stable at 11 A˚ with
a slight ﬂuctuation (Fig. 6 B).
To examine the effect of Val-179 on inhibitor binding and
unbinding, two particular snapshots of the HIV-1 RT/a-APA
complex structure in the SMD trajectory were recorded at
1250 ps (right before a-APA passes through the pocket
entrance) and at 1280 ps (right after a-APA crossed over
the entrance) (Figs. 4 and 7). Analysis of the detailed inter-
actions between a-APA and HIV-1 RT shows that when
a-APA moves toward the narrow entrance of the binding
pocket, the side chain of Val-179 apparently produces steric
clash with the acylamino group (N14) of a-APA, discour-
aging the inhibitor to escape from the binding pocket.
a-APA has to bump the Val-179 side chain away to enlarge
the entrance, so it could pass through. It is conceivable that
the increase of the distance between Leu-100 and Val-179 in
phase II is caused by the steric clash between a-APA and the
side chain of Val-179. Hence, the spatial distance between
Leu-100 and Val-179 measures the openness of the pocket
entrance and can be regarded as the bottleneck of the un-
binding pathway, which prevents the inhibitors from escape.
Inversely, we could infer that Val-179 might also act as
a guard to discriminate NNRTIs to enter into the binding
pocket during the inhibitor binding process. This would
imply that mutation of Val-179 to any residues with larger
side chains would cause more serious steric conﬂict with the
FIGURE 5 Variations of the numbers of direct hydrogen-bonding
interactions (A), water-bridged interactions (B), and hydrophobic interac-
tions (C) between a-APA and HIV-1 RT in the SMD simulation. Regions I,
II, and III denote the three phases in the unbinding process of a-APA from
the inhibitor-binding pocket. The calculation of interactions is recorded
every 10 ps.
FIGURE 6 Time dependence of (A) the distance between the Nz atoms of
Lys-101 and Lys-103 that are located at the rim of the putative entrance, and
(B) the distance between the Cb atoms of Leu-100 and Val-179 which are
located at the opposite edges of the putative entrance (see also Figs. 1 and 7).
Regions I to III denote the three phases in the unbinding process of a-APA
from the binding pocket.
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inhibitor during the inhibitor entering process and, therefore,
would discourage the inhibitor to bind. This suggestion
seems in agreement with the biochemical data that mutations
of Val-179 to Asp or Glu increase side-chain bulk and lead to
a 2- to 3-fold decrease of the binding afﬁnity (Byrnes et al.,
1993; Boyer et al., 1993).
Possible functions of Tyr-181 and Tyr-188
Site-directed mutagenesis studies show that mutations at
residues 181 and 188 affect the binding activity of NNRTIs
and confer resistance to many NNRTIs (Nunberg et al.,
1991; Richman et al., 1991; Balzarini et al., 1993).
Biochemical and structural studies indicate that the hydro-
phobic interactions between Tyr-181/Tyr-188 and NNRTIs
play an important role in the inhibitor binding (Shih et al.,
1991; Condra et al., 1992; Das et al., 1996; Hsiou et al.,
1998; Ren et al., 2001). In addition, structural studies of
HIV-1 RT indicate that binding of NNRTIs to HIV-1 RT
induces substantial conformational changes of the side
chains of Tyr-181 and Tyr-188. In the unliganded and
DNA-bound HIV-1 RT structures, the side chains of Tyr-181
and Tyr-188 in p66 both point away from the polymerase
active and ﬁll up the hydrophobic core (Jacobo-Molina et al.,
1993; Rodgers et al., 1995; Hsiou et al., 1996; Ding et al.,
1995a; Huang et al., 1998). In all NNRTI-bound HIV-1 RT
structures, these two residues rotate their side chains away
from the hydrophobic core and point toward the polymerase
active side, creating space to accommodate the inhibitor
(Kohlstaedt et al., 1992; Ding et al., 1995a,b; Ren et al.,
1995a,b, 2001; Das et al., 1996; Hsiou et al., 1998, 2001;
Lindberg et al., 2002). Our SMD simulation results indicate
that Tyr-181 makes signiﬁcant hydrophobic interactions
with a-APA during phases I and II of the unbinding process
of inhibitor. The hydrophobic interactions between Tyr-181
and a-APA vary with the simulation time, reaching 16 pairs
of NPAVDWs at maximum in phase II (Fig. 8). Though Tyr-
188 has less contribution to the hydrophobic interactions
(Fig. 5), its carbonyl group forms a strong hydrogen bond
with the acylamino group (N14) of a-APA. The hydrogen
bond length (ON14) varies between 2.6 and 3.3 A˚ and
persists for nearly 300 ps (Fig. 9).
It is suggested that the hydrophobic interactions between
the aromatic rings of NNRTIs and the side chains of Tyr-181
and Tyr-188 are important for NNRTIs binding (Ding et al.,
1995a). Analysis of the protein-inhibitor interactions shows
that the aromatic side chains of Tyr-181 and Tyr-188 are
involved in interactions with the aromatic ring A of a-APA,
but to a different extent (Fig. 10). In phases I and II (from
900 to 1300 ps), the center-to-center distance between the
aromatic ring of the side chain of Tyr-181 and aromatic ring
A of a-APA is relatively stable at 4 A˚ and the corresponding
ring-ring distance between Tyr-188 and a-APA is longer
with moderate ﬂuctuation (between 6 to 8 A˚). This is
consistent with the observation that Tyr-181 makes more
hydrophobic interactions with a-APA than Tyr-188 (see
discussion above). After the inhibitor exited the pocket
(phase III), the ring-ring distances between a-APA and Tyr-
181 and Tyr-188 increase gradually to 12 and 16 A˚,
respectively, suggesting that the hydrophobic interactions
between a-APA and the two tyrosines have been disrupted
(Fig. 10).
The relatively stable ring-ring distances between ring A of
a-APA and the side chain of Tyr-181 in phases I and II is
very interesting. It might suggest that the side chain of Tyr-
181 follows a-APA moving toward the pocket entrance.
FIGURE 7 Structures of the HIV-1 RT/a-APA complex before a-APA
passes through the bottleneck of the entrance (at 1250 ps, green) and right
after a-APA crosses over the bottleneck of the entrance (at 1280 ps, pink).
The inhibitor-binding pocket is represented by the electrostatic potential
surface. This picture was generated using WebLab ViewerPro program
(MSI, 1998) and then rendered using the POV-Ray program (Pov-Ray-
Team, 1999).
FIGURE 8 Number of van der Waals contacts involving nonpolar atoms
(NPAVWs) between a-APA and Tyr-181 versus SMD simulation time
(distance of less than 3.5 A˚).
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Analysis of the structure models from the SMD simulation
trajectory reveals that after the inhibitor left the binding
pocket the side chain of Tyr-181 has changed its conforma-
tion substantially and points toward the pocket entrance that
is similar to that observed in the unliganded HIV-1 RT
structure. In other words, as a-APA dissociates from the
binding pocket and moves toward the entrance of the pocket,
the side chain of Tyr-181 changes its conformation and tends
to occupy the empty space left over by the departing
inhibitor. On the other hand, though the side chain of Tyr-
188 appears also relatively ﬂexible, it does not change back
to the conformation as seen in the apoenzyme structure
during the SMD simulation. The reason(s) for why the side
chains of Tyr-181 and Tyr-188 behave differently after the
inhibitor exited the binding pocket is not clear yet. This
might be due, in part, to the time limitation of the simulation.
Taking together, it appears that Tyr-181 and Tyr-188 may
act as two ﬂexible clamps to interact with a-APA. The
hydrophobic and hydrogen-bonding interactions of Tyr-181
and Tyr-188 with a-APA not only stabilize the inhibitor
binding, but also prevent the inhibitor from leaving the
binding pocket. It is possible that during the inhibitor
binding process, these two residues might also facilitate
NNRTIs to enter the binding pocket and adopt an appropriate
conformation that could have the optimal interactions with
the surrounding residues.
Interactions between a-APA and water
molecules and conformational change
of a-APA at the entrance
Analysis of the protein-inhibitor interactions shows that
there are two special water molecules in the NNIBP that
appear to play important roles in the inhibitor binding and
unbinding. One is water molecule 9580 (Wat 1), which plays
an important role for the binding of a-APA with HIV-1 RT
in phase I; the other one is water molecule 9472 (Wat 2),
which is essential for the conformation change of a-APA
passing the entrance of the HIV-1 RT binding pocket. At the
beginning of the SMD simulation, Wat 1 forms a stable
water bridge, linking atom N14 of a-APA with the carbonyl
O atom of Thr-107 (Fig. 4 A). As a-APA moves toward the
pocket entrance, Wat 1 moves along with a-APA and forms
WBI(s) with residues Thr-107, Val-189, Val-179, and Gly-
190 respectively in the binding pocket along the disassoci-
ation pathway (Fig. 5 B). The strong hydrogen-bonding
interaction betweenWat 1 and atom N14 of a-APA was kept
till to the entrance of the pocket (the Wat 1N14 distance
varies between 2.6 and 3.15 A˚) (Fig. 11). In reverse, it is
quiet possible that, after a-APA enters into the binding
pocket, there is a water molecule that can regulate the
dynamic WBIs between atom N14 of a-APA and the
residues of HIV-1 RT mentioned above, orienting a-APA to
adopt a conformation having proper interaction with the
surrounding residues during the process of a-APA binding.
Wat 2 is close to Val-179 at the beginning of the SMD
simulation. When a-APA approaches to the bottleneck of the
entrance, Wat 2 competes with Wat 1 by forming water-
bridged intramolecular interactions with atoms N14, N11,
and O4 of a-APA (Fig. 4, F, I, and J). Figs. 4 and 12 clearly
show how Wat 2 squeezes out Wat 1 from atom N14 by
forming water-bridged interactions with a-APA in phase II.
At this time, the side chain of Val-179 clashes with the
acylamino group (N14) of a-APA. To avoid steric conﬂict,
the Val-179 side chain moves away to expand the pocket
entrance, and a-APA forms a folded conformation by the
acylamino group rotating toward the carbonyl group. The
WBIs between Wat 2 and a-APA facilitate the conforma-
tional folding (Figs. 7 and 13) (see following discussion).
After a-APA crossed over the bottleneck, the water-bridged
interactions diminish and a-APA gradually resumes its
unfolded conformation.
As discussed above, as a-APA passes through the
bottleneck region of the pocket entrance, a-APA bumps
the Val-179 side chain away, expanding the entrance wider.
Meanwhile, conformation of a-APA also makes substantial
FIGURE 9 Hydrogen bond distance (A˚) between the main chain oxygen
atom of Tyr-188 and the N14 atom of a-APA versus SMD simulation time.
FIGURE 10 Center-to-center distances (A˚) between the aromatic ring A
of a-APA (see Fig. 1 for deﬁnition) and the side-chain aromatic rings of Tyr-
188 (A) and Tyr-181 (B), respectively. Regions I to III denote the three
phases in the unbinding process of a-APA from the binding pocket.
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change (Figs. 7 and 13). The distance between N14 and O4
atoms of a-APA decreases markedly from 5.5 to 3 A˚ and the
dihedral angle C1-C10-N11-C12 ﬂips from 258 to 1258. The
dihedral angle between the two aromatic rings of a-APA is
compressed and a-APA adopts a folded conformation. By
doing so, a-APA can reduce the steric conﬂict with the side
chain of Val-179, making it easier to pass through the
entrance.
A quantum chemistry calculation was performed to
investigate the intrinsic relationship between the formation
of intramolecule interaction mediated by Wat 2 and the
conformational changes of a-APA. The quantum mechanics
calculations indicate the importance of Wat 2 bridged
intramolecular interactions to the conformation folding of
a-APA. Fig. 14 shows the proﬁle of the relative energy of
several representative a-APA conformations (1200, 1250,
1280, and 1310 ps) as a-APA passes through the bottleneck
of the binding pocket. The quantum mechanics calculations
indicate that the isolated a-APA conformation seen in the
crystal structure of HIV-1 RT/a-APA complex does not have
the lowest energy. The a-APA conformation of the lowest
energy is observed at 1200 ps in the SMD trajectory, which
is ;3 kcal/mol energy lower than that seen in the crystal
structure. Around the bottleneck, a-APA adopts a conforma-
tion that is ;23 kcal/mol higher than that in the crystal
structure, or ;26 kcal/mol higher than that of the lowest
energy. Such a high-energy barrier would be too costly for
a-APA to leave the binding pocket. However, the formation
of the water-bridged intramolecular hydrogen bonds induces
the conformational change of the inhibitor and/or stabilizes
the unstable conformation of a-APA of the high energy. That
signiﬁcantly lowers the energy barriers by;6.5 kcal/mol for
a-APA unbinding and 2 kcal/mol for a-APA binding,
respectively (Fig. 14).
Water molecules have been observed at the entrance of the
binding pocket and inside the binding pocket in the crystal
structures of HIV-1 RT bound with and without NNRTIs
(Ding et al., 1995b; Ren et al., 1995a,b; Hsiou, et al., 2001).
These water molecules are involved in hydrogen-bonding
interactions with several important residues at the entrance,
including Lys-101, Lys-103, Tyr-181, and Tyr-188. These
interactions are suggested to stabilize the structure of NNIBP
FIGURE 11 Variation of the hydrogen bond distance between atom N14
of a-APA and Wat 1 in the SMD simulation trajectory.
FIGURE 12 Number of the hydrogen-bonding interactions between
a-APA and Wat 1 and Wat 2 verses SMD simulation time. (A)–(D) re-
present the hydrogen bonding interactions between atoms N11, O4, N14,
and O15 of a-APA with Wat 1 and Wat 2, respectively. The hydrogen-
bonding interactions of a-APA withWat 1 andWat 2 are highlighted in gray
and light gray, respectively. Before 1150 ps, Wat 1 forms hydrogen bond
with N14 atom of a-APA. Between 1150 and 1260 ps, when a-APA passes
through the entrance, Wat 2 replaces Wat 1 to form several hydrogen bonds
with O4, N14, and N11 atoms of a-APA.
FIGURE 13 Variations of the geometric parameters of a-APA versus
simulation time in the SMD trajectory: (A) distance between N14 and O4,
(B) dihedral angle C1-C10-N11-C12, (C ) dihedral angle C10-N11-C12-
C13, (D) dihedral angle N11-C12-C16-C22, (E) dihedral angle of N11-C12-
C13-N14, and (F ) dihedral angle of C10-C1-C2-O4. The atomic numbering
of a-APA is shown in Fig. 1. Regions I to III denote the three phases in the
unbinding process of a-APA from the binding pocket.
SMD Simulation on the Binding of NNRTI to HIV-1 RT 3557
Biophysical Journal 84(6) 3547–3563
and may play important roles in steering the NNRTI entering
the pocket. Indeed, our SMD simulation results show that
water molecules do play important roles in the inhibitor
unbinding process. Some water molecules (such as Wat 1)
may be involved in stabilizing the binding of inhibitor in the
NNIBP and preventing the inhibitor’s dissociation. Other
molecules (such as Wat 2) may be involved in inducing the
inhibitor to adopt a geometric favorable conformation that
can pass through the pocket entrance during the unbinding
process. In the inhibitor binding process, water molecules
may stimulate NNRTIs to enter the binding pocket via their
interactions with the polar groups of NNRTIs.
Conformational change of the p66 subdomain:
implication for the NNRTI inhibition
mechanism to HIV-1 RT
Based on structural and biochemical data, three possible
inhibition mechanisms of NNRTIs have been postulated
(Kohlstaedt et al., 1992; Ding et al., 1995a; Das et al., 1996;
Ren et al., 1995a). The binding of NNRTIs and the formation
of NNIBP upon the inhibitor binding may 1), distort the
precise geometry and mobility of the nearby polymerase
catalytic site; 2), alter the DNA-binding cleft and restrict the
mobility of the p66 thumb subdomain which is believed to
play an important role in the translocation of template-primer
during DNA polymerization; and 3), deform the ‘‘primer
grip’’ (b12-b13 hairpin of the p66 palm subdomain) and
consequently affect the precise positioning of the primer
strand relative to the polymerase active site. All of those
hypotheses were proposed indirectly and may not be mu-
tually exclusive to each other.
To explore the relationship between NNRTIs binding and
the inhibition mechanism of HIV-1 RT, the SMD simulation
was followed by an additional 1 ns CMD simulation after a-
APA was completely pulled out from the binding pocket. For
comparison, a 2.3 ns CMD simulation was carried out on the
HIV-1 RT/a-APA complex with a-APA being constrained
in the binding pocket. Structural studies of HIV-1 RT
indicated that the p66 thumb subdomain closes down into
the DNA-binding cleft (composed of the p66 ﬁngers, palm,
and thumb subdomains) in the absence of template-primer
(Rodgers et al., 1995; Hsiou et al., 1996), and opens up to
take an upright position when template-primer is bound
(Jacobo-Molina et al., 1993; Ding et al., 1998; Huang et al.,
1998). The conformational ﬂexibility and mobility of the p66
thumb are suggested to be crucial during DNA translocation
and polymerization (Jacobo-Molina et al., 1993; Ding et al.,
1998; Huang et al., 1998).
To examine the conformational change of the p66 thumb
FIGURE 14 Proﬁles of the relative energies of a-APA conformations along the unbinding pathway of the inhibitor. A and B lines represent the proﬁles of a-
APA in the isolated state and in complex with a water molecule, respectively. All conformations of a-APA and their complexes with water molecule were
isolated from the SMD trajectory at times of 0, 1200, 1250, 1280, and 1310 ps, respectively. Dashed lines represent hydrogen-bonding interactions between a-
APA and water molecule. The relative energy of each a-APA conformer was computed using the MP2/6-31G** method by setting that of a-APA in the crystal
structure of HIV-1 RT/a-APA complex as 0.0 kcal/mol.
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subdomain and the change of the width of the DNA-binding
cleft, the domain mass center distances (DMCD) between the
p66 ﬁngers subdomain (residues 27–82 and 120–150) and
the p66 thumb subdomain (residues 241–314) were mea-
sured along the simulation trajectories for the above two MD
simulations (Fig. 15). (Hereinafter, if not noted speciﬁcally,
DMCD will refer to the domain mass center distance be-
tween the p66 ﬁngers and thumb subdomains as deﬁned
above.) Fig.15 gave the DMCD values of the three different
types of HIV-1 RT structures: the unliganded HIV-1 RT
structure (1DLO, Hsiou et al., 1996), structures of HIV-1 RT
in complexes of the template-primers (2HMI, Ding et al.,
1998; 1RTD, Huang et al., 1998), and structures of HIV-1
RT bound with NNRTIs (1HNI, Ding et al., 1995a; 1HNV,
Ding et al., 1995b; 1KLM, Esnouf et al., 1997). The DMCD
range for HIV-1 RT/NNRTIs complexes is from 45.6 to 47
A˚, that for HIV-1 RT/DNA complexes is from 39.6 to 42.7
A˚, and that for unliganded HIV-1 RT is near 26.9 A˚. It is
evident that the three types of HIV-1 RT structures (un-
liganded, DNA bound, NNRTIs bound) can be clearly
distinguished by DMCD. Therefore, DMCD can be used as
a useful indicator to investigate the conformation change of
the p66 thumb subdomain (and HIV-1 RT) along the
simulation trajectory in the inhibitor unbinding process.
In the CMD simulation, the DMCD ﬂuctuates between
45.5 and 47 A˚ throughout the whole simulation that falls in
the range of DMCDs measured from various HIV-1 RT/
NNRTIs complex structures (Fig. 15 A). This suggests that
the p66 thumb subdomain as well as the DNA-binding cleft
do not change signiﬁcantly when a-APA is constrained in
the NNIBP. On the other hand, in the SMD simulation (Fig.
15 B), the DMCD decreases slightly from 46 to 45 A˚ at the
beginning of the simulation and then reaches a stable state at
;45 A˚ when a-APA is bound in the NNIBP (phase I, from
900 to 1150 ps). As a-APA crosses over the entrance of the
binding pocket and moves from inside of the binding pocket
to the outside (phase II, from 1150 to 1300 ps), the DMCD
decreases dramatically (Fig.15 B), which indicates that the
p66 thumb subdomain starts to close accompanied by the
shrinkage of the DNA-binding cleft. The decreasing of the
DMCD continues after a-APA exited the binding pocket
(phase III, from 1300 to 1600 ps). At ;1600 ps, the DMCD
reaches ;40 A˚ that is similar to that observed in the
structures of HIV-1 RT/DNA complexes (Jacobo-Molina
et al., 1993; Huang et al., 1998; Ding et al., 1998). The p66
thumb keeps this conformation for a relatively long period of
time (from 1600 to 2250 ps) with the variation of DMCD
between 39 and 42 A˚. This suggests that the p66 thumb
closes down partially and adopts a relatively stable
conformation similar to that seen in the structures of HIV-
1 RT in complex with template-primer after the inhibitor
dissociated from the binding pocket. At ;2250 ps, the
DMCD sharply decreases to ;37 A˚ and keeps stable at this
value to the end of the simulation (Fig. 15 B). This means
that the p66 thumb continues to collapse and the DNA-
binding cleft shrinks further, but does not reach the close con-
formation of the p66 thumb as observed in the unliganded
HIV-1 RT structure (Hsiou et al., 1996).
The simulation results indicate that the p66 thumb
subdomain indeed has the conformational ﬂexibility to open
and fold down. The binding of a-APA in the NNIBP en-
larges the DNA-binding cleft and constrains the p66 thumb
in the ultra upright conformation and, therefore, restricts the
ﬂexibility and mobility of the p66 thumb. Since the DNA
binding cleft is expanded in the presence of the inhibitor, it is
probable that the binding of a-APA to HIV-1 RT should not
prohibit the binding of DNA template-primer, but may, to
some extent, destabilize the DNA binding. This suggestion
seems in agreement with the biochemical data that show that
binding of some NNRTIs to HIV-1 RT does not markedly
affect the binding of either template-primer or dNTP sub-
strates (Debyser et al., 1991; Wu et al., 1991; Maga et al.,
2000).
Taken together, the simulation results provide support for
the hypothesis of NNRTI inhibition mechanism to HIV-1 RT
that the inhibitor-binding site acts as a hinge between the p66
thumb and palm subdomains and the binding of NNRTIs
expands the DNA-binding cleft and restricts the ﬂexibility
and mobility of the p66 thumb subdomain. The constrained
p66 thumb might not be able to interact properly with the
template-primer during the recognition and translocation of
the template-primer, and consequently, impairs the poly-
merization activity of HIV-1 RT (Kohlstaedt et al., 1992;
Ding et al., 1995a).
FIGURE 15 The domain mass center distance (DMCD) between the p66
ﬁngers subdomain (residues 12–85 and 120–150) and the p66 thumb
subdomain (residue 241–314) versus simulation time: (A) the CMD
simulation and (B) the SMD simulation. The SMD simulation was followed
by a CMD simulation for 1 ns after a-APA was completely pulled out from
the inhibitor-binding pocket. The typical variation ranges of DMCDs in
different types of HIV-1 RT structures. The structures of HIV-1 RT are
denoted with their PDB entry codes as follows: structure in unliganded state,
1DLO (Hsiou et al., 1996), structures of HIV-1 RT in complexes of the
template-primers, 2HMI (Ding et al., 1998) and 1RTD (Huang et al., 1998),
and structures of HIV-1 RT bound with NNRTIs, 1HNI (Ding et al., 1995a),
1HNV (Ding et al., 1995b), and 1KLM (Esnouf et al., 1997).
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CONCLUSIONS
This work presents two nanosecond molecular dynamics
(MD) simulation studies of the unbinding process of a-APA,
an NNRTI, to HIV-1 RT. The ﬁrst was a CMD simulation in
which the inhibitor was harmonically constrained in the
NNIBP. The other was an SMD simulation in which a
harmonic potential was applied to the inhibitor to pull the
inhibitor out from the binding pocket artiﬁcially. The pulling
velocity (Vpull) is an important parameter in the SMD
simulations. The simulations at higher pulling velocity may
lead to remarkable nonequilibrium effects, which may
introduce obvious errors to the simulation results (Isralewitz
et al., 2001). The low-velocity SMD simulations that are
carried out on a millisecond time scale can overcome these
disadvantages and may reproduce actual atomic force
microscopy experiments; however, the corresponding com-
putational cost will be very expensive. However, the aim of
this study is to address the dynamical process of the
inhibitor/HIV-1 RT binding and the possible inhibition
mechanism of the NNRTIs with HIV-1 RT rather than
reproduce the accurate binding force or binding free energy.
Heymann and Grubmu¨ller (1999b) demonstrated that the
global shapes of the force proﬁles are similar under different
pulling velocities in the dissociation of AN02/DNP-hapten
complex. We had performed an SMD simulation for the
unbinding process of a-APA/HIV-1 RT complex under
a velocity of 0.05 A˚/ps (result is not shown in this paper).
The force proﬁle feature of this simulation is similar to that
of the SMD simulation at a velocity of 0.02 A˚/ps (Fig. 3).
Therefore it can be concluded that the unbinding process of
a-APA/HIV-1 RT complex may not be signiﬁcantly affected
by the pulling velocity, and that the SMD simulation result
described in this paper can be used to illustrate the inhibitor/
HIV-1 RT binding (unbinding) mechanism.
The simulation results have revealed many dynamic
features of the inhibitor unbinding process and provided
insights into the inhibition mechanism of NNRTIs. Analyses
of the force proﬁle of the SMD simulation and the
interactions between HIV-1 RT and a-APA show that the
force proﬁle in general correlates well with the protein-
inhibitor interactions. The peaks and troughs in the force
proﬁle can be associated with the formation and rupture of
speciﬁc direct and water-bridged hydrogen-bonding inter-
actions and hydrophobic interactions. The unbinding process
of a-APA can be divided into three phases based on the
position of a-APA in relation to the entrance of the binding
pocket. When a-APA dissociates from the binding pocket
and moves toward the pocket entrance (phase I), the
interactions between HIV-1 RT and a-APA are dominated
by hydrophobic interactions. However, the hydrophilic
interactions (both direct and water-bridged hydrogen bonds)
also contribute to the stabilizing forces. Whereas Tyr-181
makes signiﬁcant hydrophobic interactions with a-APA,
Tyr-188 forms strong hydrogen bond with the acylamino
group (N14) of a-APA. Moreover, during the unbinding
process of a-APA, the side chains of these two residues
change their conformations. In particular, the side chain of
Tyr-181 moves along with the inhibitor toward the pocket
entrance and tends to occupy the space left by the departing
inhibitor. These two residues appear to act as two ﬂexible
clamps discouraging a-APA to dissociate from the binding
pocket. In phase II, a-APA penetrates through the entrance
of the pocket. At the pocket entrance, two relatively
inﬂexible residues Val-179 and Leu-100 gauge the openness
of the entrance and, therefore, the spatial distance between
them appears to be the bottleneck of the inhibitor-unbinding
pathway. To escape from the binding pocket, a-APA not
only bumps the side chain of Val-179 away to expand the
size of the pocket entrance, but also folds its conformation to
reduce the steric conﬂicts with Val-179. Two water
molecules (Wat 1 and Wat 2) form water bridges between
the polar groups of the inhibitor and the residues at the
pocket entrance and between the polar groups of the
inhibitors themselves. Wat 1 seems involved in stabilizing
the binding of the inhibitor in the binding pocket and
preventing the inhibitor’s dissociation. Wat 2 seems in-
volved in inducing the inhibitor to adopt a geometric
favorable conformation so that the inhibitor can pass through
the pocket entrance. During the inhibitor binding process,
these water molecules might play important roles in inhibitor
recognition and steering it into the binding pocket. After a-
APA exits the binding pocket, the interactions between a-
APA and the protein become weaker and eventually
diminish. When the inhibitor enters the solvent region, a-
APA forms hydrogen bonds with the surrounding water
molecules and the rupture force comes primarily from the
friction force of water.
Comparison of the CMD and the SMD simulation results
shows that the binding of a-APA in the inhibitor-binding
pocket enlarges the DNA-binding cleft and constrains the
p66 thumb in an ultra upright conformation. The p66 thumb
subdomain has a great conformational ﬂexibility and tends to
fold down to adopt a closed conformation after the bound
inhibitor dissociated from the binding pocket. These results
strongly support the hypothetic mechanism of NNRTI
inhibition that the binding of NNRTIs alters the DNA-
binding cleft and restricts the ﬂexibility and mobility of the
p66 thumb subdomain that are believed to play an important
role in the translocation of the template-primer during DNA
polymerization.
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